1,062 results on '"Male Genitals"'
Search Results
152. Adenoviral E4orf3 and E4orf6 Proteins, But Not E1B55K, Increase Killing of Cancer Cells by Radiotherapy in vivo
153. Greater Biopsy Core Number Is Associated With Improved Biochemical Control in Patients Treated With Permanent Prostate Brachytherapy
154. Survivin Is a Potential Mediator of Prostate Cancer Metastasis
155. Increasing Age and Treatment Modality Are Predictors for Subsequent Diagnosis of Bladder Cancer Following Prostate Cancer Diagnosis
156. Rectal Dose-Volume Histogram Parameters Are Associated With Long-Term Patient-Reported Gastrointestinal Quality of Life After Conventional and High-Dose Radiation for Prostate Cancer: A Subgroup Analysis of a Randomized Trial
157. Clinical Evaluation of Soft Tissue Organ Boundary Visualization on Cone-Beam Computed Tomographic Imaging
158. Application of a Novel Dose-Uncertainty Model for Dose-Uncertainty Analysis in Prostate Intensity-Modulated Radiotherapy
159. A Failure Detection Strategy for Intrafraction Prostate Motion Monitoring With On-Board Imagers for Fixed-Gantry IMRT
160. Comparison Between High and Low Source Activity Seeds for I-125 Permanent Seed Prostate Brachytherapy
161. Disturbed Colonic Motility Contributes to Anorectal Symptoms and Dysfunction After Radiotherapy for Carcinoma of the Prostate
162. Clinical Toxicities and Dosimetric Parameters After Whole-Pelvis Versus Prostate-Only Intensity-Modulated Radiation Therapy for Prostate Cancer
163. PSA Decrease During Combined-Modality Radiotherapy Predicts for Treatment Outcome
164. Predicting Post-External Beam Radiation Therapy PSA Relapse of Prostate Cancer Using Pretreatment MRI
165. Phase II Trial of Combined High-Dose-Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321
166. Exposure to di(n-butyl)phthalate and benzo(a)pyrene alters IL-1{beta} secretion and subset expression of testicular macrophages, resulting in decreased testosterone production in rats
167. Evaluating the Phoenix Definition of Biochemical Failure After {sup 125}I Prostate Brachytherapy: Can PSA Kinetics Distinguish PSA Failures From PSA Bounces?
168. Optimized Hybrid Megavoltage-Kilovoltage Imaging Protocol for Volumetric Prostate Arc Therapy
169. Phase I Trial of Bortezomib and Concurrent External Beam Radiation in Patients With Advanced Solid Malignancies
170. Toxicity Analysis of Postoperative Image-Guided Intensity-Modulated Radiotherapy for Prostate Cancer
171. Sexual Function After Stereotactic Body Radiotherapy for Prostate Cancer: Results of a Prospective Clinical Trial
172. Spot Scanning Proton Beam Therapy for Prostate Cancer: Treatment Planning Technique and Analysis of Consequences of Rotational and Translational Alignment Errors
173. Biochemical Disease-Free Rate and Toxicity for Men Treated With Iodine-125 Prostate Brachytherapy With D{sub 90} {>=}180 Gy
174. Toward a Real-Time In Vivo Dosimetry System Using Plastic Scintillation Detectors
175. Ionizing Radiation Activates AMP-Activated Kinase (AMPK): A Target for Radiosensitization of Human Cancer Cells
176. Sodium Selenite Radiosensitizes Hormone-Refractory Prostate Cancer Xenograft Tumors but Not Intestinal Crypt Cells In Vivo
177. A Phase I/II Trial of Gefitinib Given Concurrently With Radiotherapy in Patients With Nonmetastatic Prostate Cancer
178. Hypofractionated Boost to the Dominant Tumor Region With Intensity Modulated Stereotactic Radiotherapy for Prostate Cancer: A Sequential Dose Escalation Pilot Study
179. Dose Gradient Near Target-Normal Structure Interface for Nonisocentric CyberKnife and Isocentric Intensity-Modulated Body Radiotherapy for Prostate Cancer
180. Correlation Between Acute and Late Toxicity in 973 Prostate Cancer Patients Treated With Three-Dimensional Conformal External Beam Radiotherapy
181. Expression of Bcl-2, p53, and MDM2 in Localized Prostate Cancer With Respect to the Outcome of Radical Radiotherapy Dose Escalation
182. A Prospective Phase III Randomized Trial of Hypofractionation Versus Conventional Fractionation in Patients With High-Risk Prostate Cancer
183. Urinary Obstruction in Prostate Cancer Patients From the Dutch Trial (68 Gy vs. 78 Gy): Relationships With Local Dose, Acute Effects, and Baseline Characteristics
184. Selective CT Angiography and Embolization of the Inferior Mesenteric Artery for Massive Bladder Hemorrhage Secondary to Locally Advanced Prostate Cancer
185. The Impact of Acute Urinary Retention After Iodine-125 Prostate Brachytherapy on Health-Related Quality of Life
186. Long-Term Outcome and Toxicity of Salvage Brachytherapy for Local Failure After Initial Radiotherapy for Prostate Cancer
187. Young Men Have Equivalent Biochemical Outcomes Compared With Older Men After Treatment With Brachytherapy for Prostate Cancer
188. Online Adaptive Replanning Method for Prostate Radiotherapy
189. Radiation-Induced Cancers From Modern Radiotherapy Techniques: Intensity-Modulated Radiotherapy Versus Proton Therapy
190. Causes of Death in Men With Prevalent Diabetes and Newly Diagnosed High- Versus Favorable-Risk Prostate Cancer
191. A Comparison of In-Room Computerized Tomography Options for Detection of Fiducial Markers in Prostate Cancer Radiotherapy
192. Prostate Localization on Daily Cone-Beam Computed Tomography Images: Accuracy Assessment of Similarity Metrics
193. Stability, Visibility, and Histologic Analysis of a New Implanted Fiducial for Use as a Kilovoltage Radiographic or Radioactive Marker for Patient Positioning and Monitoring in Radiotherapy
194. Magnetic Resonance Imaging-Defined Treatment Margins in Iodine-125 Prostate Brachytherapy
195. A New Method for Synthesizing Radiation Dose-Response Data From Multiple Trials Applied to Prostate Cancer
196. External Beam Radiation Therapy After Transurethral Resection of the Prostate: A Report on Acute and Late Genitourinary Toxicity
197. A Cinematic Magnetic Resonance Imaging Study of Milk of Magnesia Laxative and an Antiflatulent Diet to Reduce Intrafraction Prostate Motion
198. No Impairment of Quality of Life 18 Months After High-Dose Intensity-Modulated Radiotherapy for Localized Prostate Cancer: A Prospective Study
199. Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group
200. Cross-Linked Hyaluronan Gel Reduces the Acute Rectal Toxicity of Radiotherapy for Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.